Shares of OvaScience Inc. (NASDAQ:OVAS) were up 5.6% during trading on Monday . The company traded as high as $7.25 and last traded at $7.19, with a volume of 156,304 shares trading hands. The stock had previously closed at $6.81.

A number of analysts recently commented on OVAS shares. Credit Suisse Group AG reaffirmed a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Wednesday, August 10th. JMP Securities reaffirmed a “neutral” rating on shares of OvaScience in a research report on Wednesday, August 10th. Finally, JPMorgan Chase & Co. cut their price target on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $10.98.

The firm’s market cap is $264.57 million. The firm has a 50-day moving average price of $6.32 and a 200 day moving average price of $7.16.

OvaScience (NASDAQ:OVAS) last posted its earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. The company earned $0.19 million during the quarter, compared to analyst estimates of $0.21 million. OvaScience had a negative net margin of 13,906.35% and a negative return on equity of 60.10%. OvaScience’s revenue for the quarter was up 530.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.64) earnings per share. Analysts forecast that OvaScience Inc. will post ($2.66) earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. raised its stake in OvaScience by 1.0% in the second quarter. Oppenheimer & Co. Inc. now owns 52,112 shares of the company’s stock worth $271,000 after buying an additional 517 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in OvaScience by 11.4% in the second quarter. Parametric Portfolio Associates LLC now owns 39,431 shares of the company’s stock worth $205,000 after buying an additional 4,038 shares during the last quarter. Nationwide Fund Advisors increased its position in OvaScience by 31.8% in the second quarter. Nationwide Fund Advisors now owns 20,068 shares of the company’s stock worth $105,000 after buying an additional 4,846 shares during the last quarter. ProShare Advisors LLC increased its position in OvaScience by 28.7% in the second quarter. ProShare Advisors LLC now owns 29,507 shares of the company’s stock worth $154,000 after buying an additional 6,572 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in OvaScience by 2.8% in the first quarter. JPMorgan Chase & Co. now owns 341,789 shares of the company’s stock worth $3,243,000 after buying an additional 9,350 shares during the last quarter. Institutional investors own 80.70% of the company’s stock.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

5 Day Chart for NASDAQ:OVAS

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.